SlideShare ist ein Scribd-Unternehmen logo
1 von 19
Downloaden Sie, um offline zu lesen
The us pharmaceutical industry outlook to 2016 sample report
TABLE OF CONTENTS
1.     The US Pharmaceutical Industry Introduction
2.     The US Pharmaceutical Market Size, 2005-2010
3.     Top 50 Pharmaceutical Drugs in the US
4.     The US Regulations Pertaining to the Pharmaceutical Industry
              General Overview
              Health Care Reform
              Patent
5.     The US Pharmacy Distribution and Reimbursement System
6.     The US Pharmaceutical Market Segmentation
     6.1.     By Generic and Branded Drugs, 2005-2010
       6.1.1.     Generic Drugs Competitive Landscape, 2011
     6.2.     By Prescribed and Over the Counter Drugs (OTC), 2005-2010
       6.2.1.     Prescribed Drugs Market Segmentation, 2006-2010
            6.2.1.1. Top Therapeutic Classes in the US by Prescriptions Dispensed and Spending,
            2006-2010
            6.2.1.2. The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet,
            2005-2010
            6.2.1.3.   The US Prescription Drug Competitive Landscape, 2010
            6.2.1.4.   Top US Pharmacies by Total Prescription Revenues, 2011
       6.2.2.     OTC Drugs Market Segmentation, 2007-2010
     6.3.     The US Biologics/Biopharmaceutical Market
       6.3.1.     The US Biologics/Biopharmaceutical Market Size By Value, 2006-2011
       6.3.2.     Top Selling Biologic Drugs, 2010
       6.3.3.     Top US Biopharmaceutical Companies Market Share, 2011
       6.3.4.     Biologic Drugs Future Projections, 2012-2016
     6.4.     The US Specialty Drugs Market
7.     The US Pharmaceutical Industry Trends and Developments
               Rising Expenditure on Biopharmaceutical Research and Development
               Expanding Generic Drug Market
               Rising Prescription Drug Prices
               Rise in Shortage of Drugs
               Rising M&A Activities in the US Pharmaceutical Market
8.     Exports and Imports of Pharmaceticals and Medicines in the US, 2005-2010
9.     The US Pharmaceutical Industry Competitive Landscape, 2011
10.          The US Pharmaceutical Industry Future Outlook and Projections, 2011-2015
     10.1. Cause and Effect Relationship Between Industry Factors and the US Pharmaceutical
     Market Prospects
11.          Major Pharmaceutical Company Profiles
     11.1.     Pfizer Inc.
               Company Overview
               Business Strategies
               Financial Performance
     11.2.     Merck & Co.
               Company Overview
               Business Strategies
               Financial Performance
     11.3.     Novartis
               Company Overview
               Business Strategies
               Financial Performance
     11.4.     AstraZeneca
               Company Overview
               Business Strategies
Financial Performance
  11.5.     GlaxoSmithKline
            Company Overview
            Business Strategies
            Financial Performance
12.       Macro Economic and Industry Indicators: Current and Projections
  12.1.     Population, 2005-2015
  12.2.     Inpatient Admissions & Outpatients Visits, 2005-2010
  12.3.     Number of People with Health Insurance
  12.4.     Prescription Drug Price index, 2005-2015
  12.5.     Personal Disposable Income
13.       Appendix
  13.1.     Market Definition
  13.2.     Abbreviations
  13.3.     Research Methodology
            Data Collection Methods
            Approach
            Variables (Dependent and Independent)
            Multi Factor Based Sensitivity Model
            Final Conclusion
  13.4.     Disclaimer
LIST OF FIGURES
Figure 1: The US Pharmaceutical Market Size by Total Sales, in USD Billion, 2005-2010
Figure 2: The US Pharmacy Distribution and Reimbursement System
Figure 3: The US Pharmaceutical Market Segmentation by Branded and Generic Drugs on the
Basis of Revenue, in Percentage, 2005-2010
Figure 4: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the
Basis of Revenue, in Percentage, 2005-2010
Figure 5: The US Prescription Drug Competitive Landscape by Number of Prescriptions
Percentage, Million, 2010
Figure 6: The US Biopharmaceuticals Market Size by Value in USD Billion, 2006-2011
Figure 7: Market Share of the Major Biopharmaceutical Companies in the US on the Basis of
Revenue, Percentage, 2011
Figure 8: Future Projections of US Biologic Drug Sales, USD Billion, 2012-2016
Figure 9: Top Specialty Categories by Percent Contribution to Net Specialty Costs, 2010
Figure 10: The US Expenditure on Biopharmaceutical Research and Development, in USD
Billion, 2005-2010
Figure 11: Average Drug Prices for All Prescription, Branded Drugs and Generic Drugs, USD,
2005-2010
Figure 12: Number of M&A Deals in the US Pharmaceutical Sector by Value, in Number, 2010
Figure 13: The US Pharmaceutical Industry Future Projections in Terms of Sales, in USD
Billion, 2011-2015
Figure 14: The US Pharmaceutical Companies’ Market Share in Percentage, 2011
Figure 15: Pfizer Biopharmaceutical Sales in the US, in USD Billion, 2005-2011
Figure 16: Merck Pharmaceutical Drugs Sales in the US, in USD Billion, 2009-2011
Figure 17: Novartis Drug Revenue in the US, in USD Billion, 2005-2011
Figure 18: AstraZeneca Pharmaceutical Drug Sales, in USD Billion, 2005-2011
Figure 19: GlaxoSmithKline Pharmaceutical Drug Sales in the US, in USD Billion, 2007-2011
........................................................................................................Error! Bookmark not defined.
Figure 20: The US Population in Million, 2005-2015
Figure 21: Inpatient Admissions in Community Hospitals in the US, in Million, 2005-2010
Figure 22: Outpatient Visits in Community Hospitals in the US, in Million, 2005-2010
Figure 23: Total Number of People in the US with Health Insurance, in Million, 2005-2010
Figure 24: The US Prescription Drug Price Index, 2005-2015
Figure 25: Personal Disposable Income in the US, in USD Billion, 2005-2015
LIST OF TABLES
Table 1: Sales of the Top 50 Drugs in the US, in USD million, 2005-2010
Table 2: Sales of the Top 50 Drugs in the US in Million Units, 2005-2010
Table 3: Major Provisions/ Amendments in the ACA and their Impacts
Table 4: The US Pharmaceuticals Market Segmentation by Branded and Generic Drugs on the
Basis of Revenue, in USD Billion, 2005-2010
Table 5: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the
Basis of Revenue, in USD Billion, 2005-2010
Table 6: Top 10 Prescribed Drugs in the US by Dispensed Prescriptions, in Million, 2006-2010
Table 7: Top 10 Therapeutic Classes in the US by Dispensed Prescriptions, in Million, 2006-
2010
Table 8: Top 10 Therapeutic Classes in the US by Spending, in USD Billion, 2006-2010
Table 9: The US Retail Prescription Drug Sales Segmentation in Volume by Number of
Prescriptions in Type of Sales Outlet, Million, 2005-2010
Table 10: The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, USD
Billion, 2005-2010
Table 11: Top US Companies’ by Number of Prescriptions Dispensed, Million, 2010
Table 12: Top US Pharmacies by Estimated Total Prescription Revenues, USD Billion, 2011
Table 13: OTC Drugs Segmentations by Medicine Category, USD Million, 2007-2010
Table 14: The US Sales of Top Selling Global Biologic Drugs, USD billion, 2010
Table 15: Top US Companies’ by Sales of Biopharmaceutical Drugs, USD Billion, 2011
Table 16: Specialty Categories, Average Cost in USD and Relative Available Medications, 201
Table 17: Top Pharmaceutical Drugs Losing Patent Protection in 2011 and 2012
Table 18: The US Pharmaceuticals and Medicines Exports, USD Million, 2005-2010
Table 19: The US Pharmaceuticals and Medicines Imports, USD Million, 2005-2010
Table 20: US Pharmaceutical Companies’ Sales USD Billion, 2011
Table 21: The US Pharmaceutical Industry Future Projections in Terms of Sales by Prescribed
and OTC drugs, and Branded and Generic Drugs, USD Billion, 2011-2015
Table 22: Cause and Effect Relationship between Industry Factors and the US Pharmaceuticals
Industry Prospects
Table 23: Pfizer’s Product Patent Expiration Year
Table 24: Top Selling Pfizer’s Biopharmaceutical Products in the US in USD Million, and their
Revenue Contribution in Percentage, 2011
Table 25: Merck’s Top Pharmaceutical Drug Sales in US, USD Million, 2010-2011
Table 26: Novartis’ Revenue Segmentation by Pharmaceutical and Sandoz Division in the US,
USD Billion, 2005 - 2011
Table 27: Novartis’ Top Pharmaceutical Drug Sales in the US, USD Million, 2011
Table 28: Astra Zeneca’s pharmaceutical drug sales in the US by product and Therapeutic
category, in USD Million, 2011
Table 29: GlaxoSmithKline’s Top Selling Pharmaceutical Drugs in the US, in USD Million,
2011
Table 30: Demographic Distribution of Population in US on the basis of Age, in Million, 2009-
2012
Table 31: Correlation Matrix of the US Pharmaceutical Market
Table 32: Regression Coefficients Output
THE US PHARMACEUTICAL MARKET SIZE, 2005-2010
The US Pharmaceutical market is the largest pharmaceutical market in the world which has
registered a marginal slowdown in the growth rate over the period. The slowing growth rate can
be attributed to an increasing number of drugs losing its patent security and surrogated by
generic equivalents. In terms of sales value, the US pharmaceutical industry has recorded
consistent growth at a 5 year CAGR of ~ over the period. The sales of Pharmaceuticals in the US
grew from...

Figure: The US Pharmaceutical Market Size by Total Sales, in USD Billion, 2005-2010

   330.0

   320.0

   310.0

   300.0

   290.0

   280.0

   270.0

   260.0

   250.0

   240.0
               2005          2006          2007          2008          2009          2010




THE US REGULATIONS PERTAINING TO THE
PHARMACEUTICAL INDUSTRY


GENERAL OVERVIEW

Pharmaceutical companies are subject to the national, state and local laws and regulations of the
country in which they operate. In the US, the Food and Drug Administration (FDA) has authority
over the biopharmaceutical products and also manages the requirements covering the testing,
safety, effectiveness, manufacturing, labeling, marketing, advertising and post−marketing
monitoring of these biopharmaceutical products. Additionally, these companies are also subject
to the control of ….
HEALTH CARE REFORM

Patient Protection and Affordable Care Act, as revised by the Health Care and Education
Reconciliation Act was signed into law on March 23, 2010. The provisions of this Affordable
care act (ACA) will be effective in various dates over the period.
Companies are bound to pay ……..
Table: Major Provisions/ Amendments in the ACA and their Impacts

Provision    Amendment                                       Impact

                                                             


                                                             




THE US PHARMACEUTICAL MARKET SEGMENTATION


BY GENERIC AND BRANDED DRUGS, 2005-2010


Branded drugs hold the major market share in the total pharmaceutical drugs sales in the US. In
2010, branded drugs accounted for ~ of the total drugs sold, but this market share decreased over
the period from ~ in 2005. The sales of branded drugs grew from USD ~ billion in 2005 to USD
~ billion in 2010 at a CAGR of ~. Generic drugs, which showcased a growth in the market share
over the…
Figure: The US Pharmaceutical Market Segmentation by Branded and Generic Drugs on
the Basis of Revenue, in Percentage, 2005-2010

  100%
    90%
    80%
    70%
    60%
    50%
    40%
    30%
    20%
    10%
     0%
               2005      2006          2007          2008        2009       2010
                      Generic Drugs                    Branded Drugs

Figure: The US Pharmaceuticals Market Segmentation by Branded and Generic Drugs on
the Basis of Revenue, in USD Billion, 2005-2010

Sales (USD Billion)             2005          2006      2007       2008     2009        2010

Branded Drug Sales
Generic Drug Sales



BY PRESCRIBED AND OVER THE COUNTER DRUGS (OTC), 2010


Prescribed drugs commanded ~ share of the total pharmaceutical sales in the US in 2010 which
has grown from ~ in 2005. The sales of prescribed drugs has grown from USD ~ billion in 2005
to USD ~ billion in 2010 at a 5 year CAGR of ~. OTC drugs on the other hand hold …
Figure: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on
the Basis of Revenue, in Percentage, 2005-2010

 100.0%
  90.0%
  80.0%
  70.0%
  60.0%
  50.0%
  40.0%
  30.0%
  20.0%
  10.0%
   0.0%
                 2005      2006         2007             2008              2009            2010
                        OTC Drugs                            Prescribed drugs

Table: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on
the Basis of Revenue, in USD Billion, 2005-2010

Sales (USD Billion)                            2005      2006          2007         2008     2009   2010

Prescribed Drug Sales
OTC Drug Sales




THE US RETAIL PRESCRIPTION DRUG SALES SEGMENTATION BY TYPE OF
SALES OUTLET


Traditional chains are the largest sales medium for prescription drugs sales accounting for ~ of
the total sales. In 2010, ~ million prescription drugs worth USD ~ billion were sold via
traditional chains, which have grown from ~ billion worth USD ~ billion in 2005 at a 5 year
CAGR of 3.1%. Traditional chains accounted for ~ of the revenue generated from total
prescription drugs sold, and ~ of the total prescriptions dispensed in 2010. Independent stores
are the second largest sales outlet for…
Table: The US Retail Prescription Drug Sales Segmentation in Volume by Number of
Prescriptions in Type of Sales Outlet, Million, 2005-2010

Sales outlet                            2005          2006          2007          2008      2009    2010

Traditional chain
Independent

Mass merchant
Supermarkets
Mail Order

Number of prescriptions

Table: The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, USD
Billion, 2005-2010

Sales outlet                     2005        2006       2007        2008        2009       2010

Traditional chain
Independent

Mass merchant
Supermarkets
Mail Order

Retail Sales




THE US BIOLOGICS/BIOPHARMACEUTICAL MARKET


THE US BIOLOGICS/BIOPHARMACEUTICAL MARKET SIZE BY VALUE


Biologic drugs are gradually increasing their share over the period. These proteins based drugs,
mainly produced using Recombinant DNA technology, and are used increasingly to treat
numerous conditions. The Biopharmaceutical Market is booming in the US. Biological drugs are
generally more expensive than the conventional drugs thus acting as key revenue earners for
producers. The top categories of biologic drugs in terms of sales are …
Figure: The US Biopharmaceuticals Market Size by Value in USD Billion, 2006-2011
              70.0

              60.0

              50.0

              40.0
USD Billion




              30.0

              20.0

              10.0

               0.0
                       2006             2007    2008           2009            2010           2011




IMPORTS AND EXPORTS OF PHARMACETICALS AND
MEDICINES IN THE US
The imports of Pharmaceuticals and medicines have increased over the period of 5 years at a
CAGR of ~ to USD ~ billion in 2010. Pharmaceutical Preparations accounted for ~ of the total
imports, contributing USD ~ billion in 2010 which has grown from USD ~ billion in 2005 at a
CAGR of ~. Medical and botanical drugs and vitamins constituted ~ of the total
Table: The US Pharmaceuticals and Medicines Exports, USD Million, 2005-2010

NAICS
Code            Exports (USD Million)            2005     2006          2007          2008    2009    2010




Table: The US Pharmaceuticals and Medicines Imports, USD Million, 2005-2010

NAICS
Code            Imports (USD Million)          2005     2006          2007       2008        2009    2010
THE US PHARMACEUTICAL INDUSTRY FUTURE
OUTLOOK AND PROJECTIONS, 2011-2015


The US Pharmaceutical industry is among the largest pharmaceutical industries in the world and
is likely to be the leader in the future, ceteris paribus. But over the period, the development of
new and innovative blockbuster pharmaceutical drugs has been slowing down as the number of
blockbuster drugs are losing patents over the period and are being threatened by relative generic
drugs. The market share of generic drugs is increasing….
…. The US pharmaceutical industry is expected to grow over the period at a CAGR ~ with
projected sales of USD ~ billion in 2015. It is estimated that the research and development
productivity will increase and will trigger the growth in the market. Additionally the companies
will focus on …
Figure: The US Pharmaceutical Industry Future Projections in Terms of Sales, in USD
Billion, 2011-2015

                       450.0

                       400.0

                       350.0
 Sales (USD Billion)




                       300.0

                       250.0

                       200.0

                       150.0

                       100.0

                        50.0

                         0.0
                               2011   2012          2013           2014            2015

Table: The US Pharmaceutical Industry Future Projections in Terms of Sales by
Prescribed and OTC drugs, and Branded and Generic Drugs, USD Billion, 2011-2015

Drug Segmentation                            2011          2012      2013        2014        2015

Prescribed and OTC
Prescribed Drugs
OTC Drugs

  % share of Prescribed drugs
  % share of OTC drugs

  Branded and Generic
  Branded Drugs
  Generic Drugs
  % share of Branded drugs

  % share of Generic drugs




  CAUSE AND EFFECT RELATIONSHIP BETWEEN DEPENDENT AND
  INDEPENDENT FACTORS PREVAILING IN THE US
  PHARMACEUTICALS INDUSTRY
  Table: Cause and Effect Relationship between Industry Factors and the US
  Pharmaceuticals Industry Prospects

Industry Factors                    Market Impact   Comments

Increasing price of Branded drugs                   

Rising M&A activities and                           
Consolidation

Advanced Technology and                             
competitive edge in R&D and
Manufacturing

Government regulations and                          
Support

Shortage of Drugs                                   

Expansion into Emerging Markets                     

Rising Chronic Diseases                             
THE US PHARMACEUTICAL INDUSTRY COMPETITIVE
LANDSCAPE


The US pharmaceutical industry witnessed revenues worth of USD ~ billion in 2011. Pfizer is
the largest company with a market share of ~ and sales of USD ~ billion in 2011. Pfizer’s
blockbuster drug, Lipitor played a major role in helping the company secure its number one
position. With ~% market share in …

Figure: The US Pharmaceutical Companies’ Market Share in Percentage, 2011

                                         2011




Source: Company Reports

Table: The US Pharmaceutical Companies’ Sales USD Billion, 2011

Company                                                      2011 Sales (USD Billion)

Pfizer

Merck
Bristol-Myers Squibb
Roche
AstraZeneca

Novartis
Johnson & Johnson

Sanofi
Amgen
Eli Lilly
GlaxoSmithKline

Abbott Laboratories
Teva Pharmaceuticals
Others

Total US Pharmaceutical Sales




PFIZER INC.


FINANCIAL PERFORMANCE

Pfizer has shown a fluctuated growth over the period. The company witnessed sales of USD ~
billion in 2011 which has grown from USD ~ billion in 2005 at a CAGR of ~ The company
recorded decline of ~, ~ and ~ in 2007, 2008 and 2011 respectively. The 2011 revenue decrease
was due to the …
Figure: Pfizer Biopharmaceutical Sales in the US, in USD Billion, 2005-2011

                       30.0


                       25.0
 Sales (USD Billion)




                       20.0


                       15.0


                       10.0


                        5.0


                        0.0
                              2005   2006   2007   2008      2009       2010        2011
DISCLAIMER


No part of this manual or any material appearing may be reproduced, stored in or transmitted
on any other Web site without written permission of AM Mindpower Solutions and any payments
of a specified fee. Requests to republish any material may be sent to us.




For more information please refer to the below mentioned link:
http://ammindpower.com/report.php?A=256


OR
Contact at:
info@ammindpower.com

Weitere ähnliche Inhalte

Was ist angesagt?

Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Global Study Solutions - 9901366442
 
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...Antonio Iervolino
 
COVID-19 and its Impact on the Biopharma Financing and Deal Environment
COVID-19 and its Impact on the Biopharma Financing and Deal EnvironmentCOVID-19 and its Impact on the Biopharma Financing and Deal Environment
COVID-19 and its Impact on the Biopharma Financing and Deal EnvironmentTim Opler
 
Presentation Assogenerici_Biosimilars_Iervolino IMS
Presentation Assogenerici_Biosimilars_Iervolino IMSPresentation Assogenerici_Biosimilars_Iervolino IMS
Presentation Assogenerici_Biosimilars_Iervolino IMSAntonio Iervolino
 
Trends in Oncology Pharmaceuticals Business Development
Trends in Oncology Pharmaceuticals Business DevelopmentTrends in Oncology Pharmaceuticals Business Development
Trends in Oncology Pharmaceuticals Business DevelopmentTim Opler
 
M&A in pharmaceutical industry between india and italy
M&A in pharmaceutical industry between india and italyM&A in pharmaceutical industry between india and italy
M&A in pharmaceutical industry between india and italyVishal Singh
 
Pharm analysis
Pharm analysis Pharm analysis
Pharm analysis Ka Jejen
 
Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...
Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...
Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...IMARC Group
 
Emerging Biopharmaceutical Markets to Witness Exponential Growth
Emerging Biopharmaceutical Markets to Witness Exponential Growth Emerging Biopharmaceutical Markets to Witness Exponential Growth
Emerging Biopharmaceutical Markets to Witness Exponential Growth IMARC Group
 
Tr The Pharma Matters
Tr The Pharma MattersTr The Pharma Matters
Tr The Pharma MattersSyeelva
 
United States Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mul...
United States Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mul...United States Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mul...
United States Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mul...ReportsnReports
 
The economics of medical research: Public/private spillovers and the rate of ...
The economics of medical research: Public/private spillovers and the rate of ...The economics of medical research: Public/private spillovers and the rate of ...
The economics of medical research: Public/private spillovers and the rate of ...Office of Health Economics
 
Dsp investor deck william blair june 2015
Dsp investor deck william blair june 2015Dsp investor deck william blair june 2015
Dsp investor deck william blair june 2015DiplomatIR
 
World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral ...
World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral ...World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral ...
World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral ...ReportsnReports
 
Excipients in Pharmaceuticals
Excipients in PharmaceuticalsExcipients in Pharmaceuticals
Excipients in PharmaceuticalsReportLinker.com
 

Was ist angesagt? (19)

Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
 
2016-EDF-Pharma-Innovation
2016-EDF-Pharma-Innovation2016-EDF-Pharma-Innovation
2016-EDF-Pharma-Innovation
 
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
 
COVID-19 and its Impact on the Biopharma Financing and Deal Environment
COVID-19 and its Impact on the Biopharma Financing and Deal EnvironmentCOVID-19 and its Impact on the Biopharma Financing and Deal Environment
COVID-19 and its Impact on the Biopharma Financing and Deal Environment
 
Presentation Assogenerici_Biosimilars_Iervolino IMS
Presentation Assogenerici_Biosimilars_Iervolino IMSPresentation Assogenerici_Biosimilars_Iervolino IMS
Presentation Assogenerici_Biosimilars_Iervolino IMS
 
drugpricingstudy
drugpricingstudydrugpricingstudy
drugpricingstudy
 
Trends in Oncology Pharmaceuticals Business Development
Trends in Oncology Pharmaceuticals Business DevelopmentTrends in Oncology Pharmaceuticals Business Development
Trends in Oncology Pharmaceuticals Business Development
 
M&A in pharmaceutical industry between india and italy
M&A in pharmaceutical industry between india and italyM&A in pharmaceutical industry between india and italy
M&A in pharmaceutical industry between india and italy
 
Pharm analysis
Pharm analysis Pharm analysis
Pharm analysis
 
Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...
Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...
Orphan drugs market Report with Leading Competitor Analysis, Strategies and F...
 
Emerging Biopharmaceutical Markets to Witness Exponential Growth
Emerging Biopharmaceutical Markets to Witness Exponential Growth Emerging Biopharmaceutical Markets to Witness Exponential Growth
Emerging Biopharmaceutical Markets to Witness Exponential Growth
 
Global diabetes care_market_cmd2011
Global diabetes care_market_cmd2011Global diabetes care_market_cmd2011
Global diabetes care_market_cmd2011
 
Final
FinalFinal
Final
 
Tr The Pharma Matters
Tr The Pharma MattersTr The Pharma Matters
Tr The Pharma Matters
 
United States Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mul...
United States Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mul...United States Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mul...
United States Patient Monitoring Market Outlook to 2018 - Fetal Monitors, Mul...
 
The economics of medical research: Public/private spillovers and the rate of ...
The economics of medical research: Public/private spillovers and the rate of ...The economics of medical research: Public/private spillovers and the rate of ...
The economics of medical research: Public/private spillovers and the rate of ...
 
Dsp investor deck william blair june 2015
Dsp investor deck william blair june 2015Dsp investor deck william blair june 2015
Dsp investor deck william blair june 2015
 
World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral ...
World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral ...World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral ...
World Market for Clinical Nutrition Products (Infant, Parenteral and Enteral ...
 
Excipients in Pharmaceuticals
Excipients in PharmaceuticalsExcipients in Pharmaceuticals
Excipients in Pharmaceuticals
 

Ähnlich wie The us pharmaceutical industry outlook to 2016 sample report

China pharmaceutical industry research & forecast to 2016 sample report
China pharmaceutical industry research & forecast to 2016 sample reportChina pharmaceutical industry research & forecast to 2016 sample report
China pharmaceutical industry research & forecast to 2016 sample reportAMMindpower
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9Yousaf Khan
 
The Pharmaceutical Market: Canada
The Pharmaceutical Market: CanadaThe Pharmaceutical Market: Canada
The Pharmaceutical Market: CanadaJames Parker
 
Global Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisGlobal Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisAiswariya Chidambaram
 
Us orphan drug market outlook 2018
Us orphan drug market outlook 2018Us orphan drug market outlook 2018
Us orphan drug market outlook 2018Rajesh Sarma
 
Pharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & IndianPharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & Indianprateek_floyd
 
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerAntitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerNexsen Pruet
 
Healthcare, regulatory and reimbursement landscape israel
Healthcare, regulatory and reimbursement landscape   israelHealthcare, regulatory and reimbursement landscape   israel
Healthcare, regulatory and reimbursement landscape israelsalisonline
 
Us biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisUs biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisRajesh Sarma
 
Download Us biosimilars market opportunity & clinical pipeline analysis
Download Us biosimilars market opportunity & clinical pipeline analysisDownload Us biosimilars market opportunity & clinical pipeline analysis
Download Us biosimilars market opportunity & clinical pipeline analysisKuicK Research
 
The Economic Impact Of Medical Tourism
The Economic Impact Of Medical TourismThe Economic Impact Of Medical Tourism
The Economic Impact Of Medical TourismDavid Vequist
 
Pharmaceutical Industry Analytics
Pharmaceutical Industry AnalyticsPharmaceutical Industry Analytics
Pharmaceutical Industry AnalyticsJatin Arora
 
USA FAQs- Prescription Drug Pricing & Policy
USA FAQs- Prescription Drug Pricing & PolicyUSA FAQs- Prescription Drug Pricing & Policy
USA FAQs- Prescription Drug Pricing & PolicyDr Dev Kambhampati
 
Financial Management in Pharmaceutical industry
Financial Management in Pharmaceutical industryFinancial Management in Pharmaceutical industry
Financial Management in Pharmaceutical industryDr.Richa S
 
Healthcare, Regulatory and Reimbursement Landscape - Israel
Healthcare, Regulatory and Reimbursement Landscape - IsraelHealthcare, Regulatory and Reimbursement Landscape - Israel
Healthcare, Regulatory and Reimbursement Landscape - IsraelReportsnReports
 
North America Animal Health Care Market Outlook to 2016 - Recuperating US Vet...
North America Animal Health Care Market Outlook to 2016 - Recuperating US Vet...North America Animal Health Care Market Outlook to 2016 - Recuperating US Vet...
North America Animal Health Care Market Outlook to 2016 - Recuperating US Vet...AMMindpower
 
The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketingFarhad Zargari
 
Pharmaceutical Drugs Essay
Pharmaceutical Drugs EssayPharmaceutical Drugs Essay
Pharmaceutical Drugs EssayNicole Williams
 

Ähnlich wie The us pharmaceutical industry outlook to 2016 sample report (20)

China pharmaceutical industry research & forecast to 2016 sample report
China pharmaceutical industry research & forecast to 2016 sample reportChina pharmaceutical industry research & forecast to 2016 sample report
China pharmaceutical industry research & forecast to 2016 sample report
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9
 
Pharmacy Presentation
Pharmacy PresentationPharmacy Presentation
Pharmacy Presentation
 
The Pharmaceutical Market: Canada
The Pharmaceutical Market: CanadaThe Pharmaceutical Market: Canada
The Pharmaceutical Market: Canada
 
Global Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisGlobal Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
Global Generic Pharmaceutical Market - Qualitative and Quantitative Analysis
 
Us orphan drug market outlook 2018
Us orphan drug market outlook 2018Us orphan drug market outlook 2018
Us orphan drug market outlook 2018
 
Pharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & IndianPharmaceutical Industry Global & Indian
Pharmaceutical Industry Global & Indian
 
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerAntitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
 
Healthcare, regulatory and reimbursement landscape israel
Healthcare, regulatory and reimbursement landscape   israelHealthcare, regulatory and reimbursement landscape   israel
Healthcare, regulatory and reimbursement landscape israel
 
Us biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysisUs biosimilars market opportunity & clinical pipeline analysis
Us biosimilars market opportunity & clinical pipeline analysis
 
Download Us biosimilars market opportunity & clinical pipeline analysis
Download Us biosimilars market opportunity & clinical pipeline analysisDownload Us biosimilars market opportunity & clinical pipeline analysis
Download Us biosimilars market opportunity & clinical pipeline analysis
 
The Economic Impact Of Medical Tourism
The Economic Impact Of Medical TourismThe Economic Impact Of Medical Tourism
The Economic Impact Of Medical Tourism
 
Pharmaceutical Industry Analytics
Pharmaceutical Industry AnalyticsPharmaceutical Industry Analytics
Pharmaceutical Industry Analytics
 
Pakistan Pharma Overview
Pakistan Pharma OverviewPakistan Pharma Overview
Pakistan Pharma Overview
 
USA FAQs- Prescription Drug Pricing & Policy
USA FAQs- Prescription Drug Pricing & PolicyUSA FAQs- Prescription Drug Pricing & Policy
USA FAQs- Prescription Drug Pricing & Policy
 
Financial Management in Pharmaceutical industry
Financial Management in Pharmaceutical industryFinancial Management in Pharmaceutical industry
Financial Management in Pharmaceutical industry
 
Healthcare, Regulatory and Reimbursement Landscape - Israel
Healthcare, Regulatory and Reimbursement Landscape - IsraelHealthcare, Regulatory and Reimbursement Landscape - Israel
Healthcare, Regulatory and Reimbursement Landscape - Israel
 
North America Animal Health Care Market Outlook to 2016 - Recuperating US Vet...
North America Animal Health Care Market Outlook to 2016 - Recuperating US Vet...North America Animal Health Care Market Outlook to 2016 - Recuperating US Vet...
North America Animal Health Care Market Outlook to 2016 - Recuperating US Vet...
 
The future of pharma marketing
The future of pharma marketingThe future of pharma marketing
The future of pharma marketing
 
Pharmaceutical Drugs Essay
Pharmaceutical Drugs EssayPharmaceutical Drugs Essay
Pharmaceutical Drugs Essay
 

Mehr von AMMindpower

Global Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS Market
Global Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS MarketGlobal Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS Market
Global Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS MarketAMMindpower
 
The Indian Innerwear Market Outlook to 2015 - Growth Opportunity for Internat...
The Indian Innerwear Market Outlook to 2015 - Growth Opportunity for Internat...The Indian Innerwear Market Outlook to 2015 - Growth Opportunity for Internat...
The Indian Innerwear Market Outlook to 2015 - Growth Opportunity for Internat...AMMindpower
 
Europe Animal Health Care Market Outlook to 2016 – Surging Expenditure on Pets
Europe Animal Health Care Market Outlook to 2016 – Surging Expenditure on PetsEurope Animal Health Care Market Outlook to 2016 – Surging Expenditure on Pets
Europe Animal Health Care Market Outlook to 2016 – Surging Expenditure on PetsAMMindpower
 
Latin America Animal Health Care Market Outlook to 2016 - Demand for Dairy an...
Latin America Animal Health Care Market Outlook to 2016 - Demand for Dairy an...Latin America Animal Health Care Market Outlook to 2016 - Demand for Dairy an...
Latin America Animal Health Care Market Outlook to 2016 - Demand for Dairy an...AMMindpower
 
Asia Pacific Animal Health Care Market Outlook to 2016 - Compelling Potential...
Asia Pacific Animal Health Care Market Outlook to 2016 - Compelling Potential...Asia Pacific Animal Health Care Market Outlook to 2016 - Compelling Potential...
Asia Pacific Animal Health Care Market Outlook to 2016 - Compelling Potential...AMMindpower
 
Global Animal Health Care Market Outlook to 2016 - Growth Opportunity in the ...
Global Animal Health Care Market Outlook to 2016 - Growth Opportunity in the ...Global Animal Health Care Market Outlook to 2016 - Growth Opportunity in the ...
Global Animal Health Care Market Outlook to 2016 - Growth Opportunity in the ...AMMindpower
 
Brazil petroleum and natural gas market outlook to 2016 executive summary
Brazil petroleum and natural gas market outlook to 2016 executive summaryBrazil petroleum and natural gas market outlook to 2016 executive summary
Brazil petroleum and natural gas market outlook to 2016 executive summaryAMMindpower
 
Baby food and infant formula market in china outlook to 2016
Baby food and infant formula market in china outlook to 2016Baby food and infant formula market in china outlook to 2016
Baby food and infant formula market in china outlook to 2016AMMindpower
 
Indian auto components industry outlook edition 2012
Indian auto components industry outlook edition 2012Indian auto components industry outlook edition 2012
Indian auto components industry outlook edition 2012AMMindpower
 
Europe crop protection industry outlook to 2016 sample report
Europe  crop protection industry outlook to 2016 sample reportEurope  crop protection industry outlook to 2016 sample report
Europe crop protection industry outlook to 2016 sample reportAMMindpower
 
Global crop protection industry outlook to 2016 sample report
Global crop protection industry outlook to 2016 sample reportGlobal crop protection industry outlook to 2016 sample report
Global crop protection industry outlook to 2016 sample reportAMMindpower
 
Nafta crop protection industry outlook to 2016 sample report
Nafta crop protection industry outlook to 2016  sample reportNafta crop protection industry outlook to 2016  sample report
Nafta crop protection industry outlook to 2016 sample reportAMMindpower
 
Global crop protection industry outlook to 2016 sample report
Global crop protection industry outlook to 2016 sample reportGlobal crop protection industry outlook to 2016 sample report
Global crop protection industry outlook to 2016 sample reportAMMindpower
 
Europe crop protection industry outlook to 2016 sample report
Europe  crop protection industry outlook to 2016 sample reportEurope  crop protection industry outlook to 2016 sample report
Europe crop protection industry outlook to 2016 sample reportAMMindpower
 
The us replacement tires industry outlook to 2016 sample report
The us replacement tires industry outlook to 2016 sample reportThe us replacement tires industry outlook to 2016 sample report
The us replacement tires industry outlook to 2016 sample reportAMMindpower
 
Middle east real estate market outlook sample report
Middle east real estate market outlook sample reportMiddle east real estate market outlook sample report
Middle east real estate market outlook sample reportAMMindpower
 
The us apparel and footwear industry outlook to 2015 sample file
The us apparel and footwear industry outlook to 2015 sample fileThe us apparel and footwear industry outlook to 2015 sample file
The us apparel and footwear industry outlook to 2015 sample fileAMMindpower
 
The Patients from Middle East Accounted for a Significant Share of Total Fore...
The Patients from Middle East Accounted for a Significant Share of Total Fore...The Patients from Middle East Accounted for a Significant Share of Total Fore...
The Patients from Middle East Accounted for a Significant Share of Total Fore...AMMindpower
 
Strong Recovery Expected in Thailand Medical Tourism in 2012
Strong Recovery Expected in Thailand Medical Tourism in 2012Strong Recovery Expected in Thailand Medical Tourism in 2012
Strong Recovery Expected in Thailand Medical Tourism in 2012AMMindpower
 
Total Foreign Patients Treated in Asia are Expected to Increase to 6,785 Thou...
Total Foreign Patients Treated in Asia are Expected to Increase to 6,785 Thou...Total Foreign Patients Treated in Asia are Expected to Increase to 6,785 Thou...
Total Foreign Patients Treated in Asia are Expected to Increase to 6,785 Thou...AMMindpower
 

Mehr von AMMindpower (20)

Global Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS Market
Global Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS MarketGlobal Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS Market
Global Healthcare IT Market Outlook to 2016 - Evolving mHealth and PACS Market
 
The Indian Innerwear Market Outlook to 2015 - Growth Opportunity for Internat...
The Indian Innerwear Market Outlook to 2015 - Growth Opportunity for Internat...The Indian Innerwear Market Outlook to 2015 - Growth Opportunity for Internat...
The Indian Innerwear Market Outlook to 2015 - Growth Opportunity for Internat...
 
Europe Animal Health Care Market Outlook to 2016 – Surging Expenditure on Pets
Europe Animal Health Care Market Outlook to 2016 – Surging Expenditure on PetsEurope Animal Health Care Market Outlook to 2016 – Surging Expenditure on Pets
Europe Animal Health Care Market Outlook to 2016 – Surging Expenditure on Pets
 
Latin America Animal Health Care Market Outlook to 2016 - Demand for Dairy an...
Latin America Animal Health Care Market Outlook to 2016 - Demand for Dairy an...Latin America Animal Health Care Market Outlook to 2016 - Demand for Dairy an...
Latin America Animal Health Care Market Outlook to 2016 - Demand for Dairy an...
 
Asia Pacific Animal Health Care Market Outlook to 2016 - Compelling Potential...
Asia Pacific Animal Health Care Market Outlook to 2016 - Compelling Potential...Asia Pacific Animal Health Care Market Outlook to 2016 - Compelling Potential...
Asia Pacific Animal Health Care Market Outlook to 2016 - Compelling Potential...
 
Global Animal Health Care Market Outlook to 2016 - Growth Opportunity in the ...
Global Animal Health Care Market Outlook to 2016 - Growth Opportunity in the ...Global Animal Health Care Market Outlook to 2016 - Growth Opportunity in the ...
Global Animal Health Care Market Outlook to 2016 - Growth Opportunity in the ...
 
Brazil petroleum and natural gas market outlook to 2016 executive summary
Brazil petroleum and natural gas market outlook to 2016 executive summaryBrazil petroleum and natural gas market outlook to 2016 executive summary
Brazil petroleum and natural gas market outlook to 2016 executive summary
 
Baby food and infant formula market in china outlook to 2016
Baby food and infant formula market in china outlook to 2016Baby food and infant formula market in china outlook to 2016
Baby food and infant formula market in china outlook to 2016
 
Indian auto components industry outlook edition 2012
Indian auto components industry outlook edition 2012Indian auto components industry outlook edition 2012
Indian auto components industry outlook edition 2012
 
Europe crop protection industry outlook to 2016 sample report
Europe  crop protection industry outlook to 2016 sample reportEurope  crop protection industry outlook to 2016 sample report
Europe crop protection industry outlook to 2016 sample report
 
Global crop protection industry outlook to 2016 sample report
Global crop protection industry outlook to 2016 sample reportGlobal crop protection industry outlook to 2016 sample report
Global crop protection industry outlook to 2016 sample report
 
Nafta crop protection industry outlook to 2016 sample report
Nafta crop protection industry outlook to 2016  sample reportNafta crop protection industry outlook to 2016  sample report
Nafta crop protection industry outlook to 2016 sample report
 
Global crop protection industry outlook to 2016 sample report
Global crop protection industry outlook to 2016 sample reportGlobal crop protection industry outlook to 2016 sample report
Global crop protection industry outlook to 2016 sample report
 
Europe crop protection industry outlook to 2016 sample report
Europe  crop protection industry outlook to 2016 sample reportEurope  crop protection industry outlook to 2016 sample report
Europe crop protection industry outlook to 2016 sample report
 
The us replacement tires industry outlook to 2016 sample report
The us replacement tires industry outlook to 2016 sample reportThe us replacement tires industry outlook to 2016 sample report
The us replacement tires industry outlook to 2016 sample report
 
Middle east real estate market outlook sample report
Middle east real estate market outlook sample reportMiddle east real estate market outlook sample report
Middle east real estate market outlook sample report
 
The us apparel and footwear industry outlook to 2015 sample file
The us apparel and footwear industry outlook to 2015 sample fileThe us apparel and footwear industry outlook to 2015 sample file
The us apparel and footwear industry outlook to 2015 sample file
 
The Patients from Middle East Accounted for a Significant Share of Total Fore...
The Patients from Middle East Accounted for a Significant Share of Total Fore...The Patients from Middle East Accounted for a Significant Share of Total Fore...
The Patients from Middle East Accounted for a Significant Share of Total Fore...
 
Strong Recovery Expected in Thailand Medical Tourism in 2012
Strong Recovery Expected in Thailand Medical Tourism in 2012Strong Recovery Expected in Thailand Medical Tourism in 2012
Strong Recovery Expected in Thailand Medical Tourism in 2012
 
Total Foreign Patients Treated in Asia are Expected to Increase to 6,785 Thou...
Total Foreign Patients Treated in Asia are Expected to Increase to 6,785 Thou...Total Foreign Patients Treated in Asia are Expected to Increase to 6,785 Thou...
Total Foreign Patients Treated in Asia are Expected to Increase to 6,785 Thou...
 

Kürzlich hochgeladen

ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 

Kürzlich hochgeladen (20)

ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 

The us pharmaceutical industry outlook to 2016 sample report

  • 2. TABLE OF CONTENTS 1. The US Pharmaceutical Industry Introduction 2. The US Pharmaceutical Market Size, 2005-2010 3. Top 50 Pharmaceutical Drugs in the US 4. The US Regulations Pertaining to the Pharmaceutical Industry General Overview Health Care Reform Patent 5. The US Pharmacy Distribution and Reimbursement System 6. The US Pharmaceutical Market Segmentation 6.1. By Generic and Branded Drugs, 2005-2010 6.1.1. Generic Drugs Competitive Landscape, 2011 6.2. By Prescribed and Over the Counter Drugs (OTC), 2005-2010 6.2.1. Prescribed Drugs Market Segmentation, 2006-2010 6.2.1.1. Top Therapeutic Classes in the US by Prescriptions Dispensed and Spending, 2006-2010 6.2.1.2. The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, 2005-2010 6.2.1.3. The US Prescription Drug Competitive Landscape, 2010 6.2.1.4. Top US Pharmacies by Total Prescription Revenues, 2011 6.2.2. OTC Drugs Market Segmentation, 2007-2010 6.3. The US Biologics/Biopharmaceutical Market 6.3.1. The US Biologics/Biopharmaceutical Market Size By Value, 2006-2011 6.3.2. Top Selling Biologic Drugs, 2010 6.3.3. Top US Biopharmaceutical Companies Market Share, 2011 6.3.4. Biologic Drugs Future Projections, 2012-2016 6.4. The US Specialty Drugs Market
  • 3. 7. The US Pharmaceutical Industry Trends and Developments Rising Expenditure on Biopharmaceutical Research and Development Expanding Generic Drug Market Rising Prescription Drug Prices Rise in Shortage of Drugs Rising M&A Activities in the US Pharmaceutical Market 8. Exports and Imports of Pharmaceticals and Medicines in the US, 2005-2010 9. The US Pharmaceutical Industry Competitive Landscape, 2011 10. The US Pharmaceutical Industry Future Outlook and Projections, 2011-2015 10.1. Cause and Effect Relationship Between Industry Factors and the US Pharmaceutical Market Prospects 11. Major Pharmaceutical Company Profiles 11.1. Pfizer Inc. Company Overview Business Strategies Financial Performance 11.2. Merck & Co. Company Overview Business Strategies Financial Performance 11.3. Novartis Company Overview Business Strategies Financial Performance 11.4. AstraZeneca Company Overview Business Strategies
  • 4. Financial Performance 11.5. GlaxoSmithKline Company Overview Business Strategies Financial Performance 12. Macro Economic and Industry Indicators: Current and Projections 12.1. Population, 2005-2015 12.2. Inpatient Admissions & Outpatients Visits, 2005-2010 12.3. Number of People with Health Insurance 12.4. Prescription Drug Price index, 2005-2015 12.5. Personal Disposable Income 13. Appendix 13.1. Market Definition 13.2. Abbreviations 13.3. Research Methodology Data Collection Methods Approach Variables (Dependent and Independent) Multi Factor Based Sensitivity Model Final Conclusion 13.4. Disclaimer
  • 5. LIST OF FIGURES Figure 1: The US Pharmaceutical Market Size by Total Sales, in USD Billion, 2005-2010 Figure 2: The US Pharmacy Distribution and Reimbursement System Figure 3: The US Pharmaceutical Market Segmentation by Branded and Generic Drugs on the Basis of Revenue, in Percentage, 2005-2010 Figure 4: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the Basis of Revenue, in Percentage, 2005-2010 Figure 5: The US Prescription Drug Competitive Landscape by Number of Prescriptions Percentage, Million, 2010 Figure 6: The US Biopharmaceuticals Market Size by Value in USD Billion, 2006-2011 Figure 7: Market Share of the Major Biopharmaceutical Companies in the US on the Basis of Revenue, Percentage, 2011 Figure 8: Future Projections of US Biologic Drug Sales, USD Billion, 2012-2016 Figure 9: Top Specialty Categories by Percent Contribution to Net Specialty Costs, 2010 Figure 10: The US Expenditure on Biopharmaceutical Research and Development, in USD Billion, 2005-2010 Figure 11: Average Drug Prices for All Prescription, Branded Drugs and Generic Drugs, USD, 2005-2010 Figure 12: Number of M&A Deals in the US Pharmaceutical Sector by Value, in Number, 2010 Figure 13: The US Pharmaceutical Industry Future Projections in Terms of Sales, in USD Billion, 2011-2015 Figure 14: The US Pharmaceutical Companies’ Market Share in Percentage, 2011 Figure 15: Pfizer Biopharmaceutical Sales in the US, in USD Billion, 2005-2011 Figure 16: Merck Pharmaceutical Drugs Sales in the US, in USD Billion, 2009-2011 Figure 17: Novartis Drug Revenue in the US, in USD Billion, 2005-2011 Figure 18: AstraZeneca Pharmaceutical Drug Sales, in USD Billion, 2005-2011 Figure 19: GlaxoSmithKline Pharmaceutical Drug Sales in the US, in USD Billion, 2007-2011 ........................................................................................................Error! Bookmark not defined. Figure 20: The US Population in Million, 2005-2015
  • 6. Figure 21: Inpatient Admissions in Community Hospitals in the US, in Million, 2005-2010 Figure 22: Outpatient Visits in Community Hospitals in the US, in Million, 2005-2010 Figure 23: Total Number of People in the US with Health Insurance, in Million, 2005-2010 Figure 24: The US Prescription Drug Price Index, 2005-2015 Figure 25: Personal Disposable Income in the US, in USD Billion, 2005-2015
  • 7. LIST OF TABLES Table 1: Sales of the Top 50 Drugs in the US, in USD million, 2005-2010 Table 2: Sales of the Top 50 Drugs in the US in Million Units, 2005-2010 Table 3: Major Provisions/ Amendments in the ACA and their Impacts Table 4: The US Pharmaceuticals Market Segmentation by Branded and Generic Drugs on the Basis of Revenue, in USD Billion, 2005-2010 Table 5: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the Basis of Revenue, in USD Billion, 2005-2010 Table 6: Top 10 Prescribed Drugs in the US by Dispensed Prescriptions, in Million, 2006-2010 Table 7: Top 10 Therapeutic Classes in the US by Dispensed Prescriptions, in Million, 2006- 2010 Table 8: Top 10 Therapeutic Classes in the US by Spending, in USD Billion, 2006-2010 Table 9: The US Retail Prescription Drug Sales Segmentation in Volume by Number of Prescriptions in Type of Sales Outlet, Million, 2005-2010 Table 10: The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, USD Billion, 2005-2010 Table 11: Top US Companies’ by Number of Prescriptions Dispensed, Million, 2010 Table 12: Top US Pharmacies by Estimated Total Prescription Revenues, USD Billion, 2011 Table 13: OTC Drugs Segmentations by Medicine Category, USD Million, 2007-2010 Table 14: The US Sales of Top Selling Global Biologic Drugs, USD billion, 2010 Table 15: Top US Companies’ by Sales of Biopharmaceutical Drugs, USD Billion, 2011 Table 16: Specialty Categories, Average Cost in USD and Relative Available Medications, 201 Table 17: Top Pharmaceutical Drugs Losing Patent Protection in 2011 and 2012 Table 18: The US Pharmaceuticals and Medicines Exports, USD Million, 2005-2010 Table 19: The US Pharmaceuticals and Medicines Imports, USD Million, 2005-2010 Table 20: US Pharmaceutical Companies’ Sales USD Billion, 2011 Table 21: The US Pharmaceutical Industry Future Projections in Terms of Sales by Prescribed and OTC drugs, and Branded and Generic Drugs, USD Billion, 2011-2015
  • 8. Table 22: Cause and Effect Relationship between Industry Factors and the US Pharmaceuticals Industry Prospects Table 23: Pfizer’s Product Patent Expiration Year Table 24: Top Selling Pfizer’s Biopharmaceutical Products in the US in USD Million, and their Revenue Contribution in Percentage, 2011 Table 25: Merck’s Top Pharmaceutical Drug Sales in US, USD Million, 2010-2011 Table 26: Novartis’ Revenue Segmentation by Pharmaceutical and Sandoz Division in the US, USD Billion, 2005 - 2011 Table 27: Novartis’ Top Pharmaceutical Drug Sales in the US, USD Million, 2011 Table 28: Astra Zeneca’s pharmaceutical drug sales in the US by product and Therapeutic category, in USD Million, 2011 Table 29: GlaxoSmithKline’s Top Selling Pharmaceutical Drugs in the US, in USD Million, 2011 Table 30: Demographic Distribution of Population in US on the basis of Age, in Million, 2009- 2012 Table 31: Correlation Matrix of the US Pharmaceutical Market Table 32: Regression Coefficients Output
  • 9. THE US PHARMACEUTICAL MARKET SIZE, 2005-2010 The US Pharmaceutical market is the largest pharmaceutical market in the world which has registered a marginal slowdown in the growth rate over the period. The slowing growth rate can be attributed to an increasing number of drugs losing its patent security and surrogated by generic equivalents. In terms of sales value, the US pharmaceutical industry has recorded consistent growth at a 5 year CAGR of ~ over the period. The sales of Pharmaceuticals in the US grew from... Figure: The US Pharmaceutical Market Size by Total Sales, in USD Billion, 2005-2010 330.0 320.0 310.0 300.0 290.0 280.0 270.0 260.0 250.0 240.0 2005 2006 2007 2008 2009 2010 THE US REGULATIONS PERTAINING TO THE PHARMACEUTICAL INDUSTRY GENERAL OVERVIEW Pharmaceutical companies are subject to the national, state and local laws and regulations of the country in which they operate. In the US, the Food and Drug Administration (FDA) has authority over the biopharmaceutical products and also manages the requirements covering the testing, safety, effectiveness, manufacturing, labeling, marketing, advertising and post−marketing monitoring of these biopharmaceutical products. Additionally, these companies are also subject to the control of ….
  • 10. HEALTH CARE REFORM Patient Protection and Affordable Care Act, as revised by the Health Care and Education Reconciliation Act was signed into law on March 23, 2010. The provisions of this Affordable care act (ACA) will be effective in various dates over the period. Companies are bound to pay …….. Table: Major Provisions/ Amendments in the ACA and their Impacts Provision Amendment Impact     THE US PHARMACEUTICAL MARKET SEGMENTATION BY GENERIC AND BRANDED DRUGS, 2005-2010 Branded drugs hold the major market share in the total pharmaceutical drugs sales in the US. In 2010, branded drugs accounted for ~ of the total drugs sold, but this market share decreased over the period from ~ in 2005. The sales of branded drugs grew from USD ~ billion in 2005 to USD ~ billion in 2010 at a CAGR of ~. Generic drugs, which showcased a growth in the market share over the…
  • 11. Figure: The US Pharmaceutical Market Segmentation by Branded and Generic Drugs on the Basis of Revenue, in Percentage, 2005-2010 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2005 2006 2007 2008 2009 2010 Generic Drugs Branded Drugs Figure: The US Pharmaceuticals Market Segmentation by Branded and Generic Drugs on the Basis of Revenue, in USD Billion, 2005-2010 Sales (USD Billion) 2005 2006 2007 2008 2009 2010 Branded Drug Sales Generic Drug Sales BY PRESCRIBED AND OVER THE COUNTER DRUGS (OTC), 2010 Prescribed drugs commanded ~ share of the total pharmaceutical sales in the US in 2010 which has grown from ~ in 2005. The sales of prescribed drugs has grown from USD ~ billion in 2005 to USD ~ billion in 2010 at a 5 year CAGR of ~. OTC drugs on the other hand hold …
  • 12. Figure: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the Basis of Revenue, in Percentage, 2005-2010 100.0% 90.0% 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 2005 2006 2007 2008 2009 2010 OTC Drugs Prescribed drugs Table: The US Pharmaceuticals Market Segmentation by Prescribed and OTC Drugs on the Basis of Revenue, in USD Billion, 2005-2010 Sales (USD Billion) 2005 2006 2007 2008 2009 2010 Prescribed Drug Sales OTC Drug Sales THE US RETAIL PRESCRIPTION DRUG SALES SEGMENTATION BY TYPE OF SALES OUTLET Traditional chains are the largest sales medium for prescription drugs sales accounting for ~ of the total sales. In 2010, ~ million prescription drugs worth USD ~ billion were sold via traditional chains, which have grown from ~ billion worth USD ~ billion in 2005 at a 5 year CAGR of 3.1%. Traditional chains accounted for ~ of the revenue generated from total prescription drugs sold, and ~ of the total prescriptions dispensed in 2010. Independent stores are the second largest sales outlet for… Table: The US Retail Prescription Drug Sales Segmentation in Volume by Number of Prescriptions in Type of Sales Outlet, Million, 2005-2010 Sales outlet 2005 2006 2007 2008 2009 2010 Traditional chain
  • 13. Independent Mass merchant Supermarkets Mail Order Number of prescriptions Table: The US Retail Prescription Drug Sales Segmentation by Type of Sales Outlet, USD Billion, 2005-2010 Sales outlet 2005 2006 2007 2008 2009 2010 Traditional chain Independent Mass merchant Supermarkets Mail Order Retail Sales THE US BIOLOGICS/BIOPHARMACEUTICAL MARKET THE US BIOLOGICS/BIOPHARMACEUTICAL MARKET SIZE BY VALUE Biologic drugs are gradually increasing their share over the period. These proteins based drugs, mainly produced using Recombinant DNA technology, and are used increasingly to treat numerous conditions. The Biopharmaceutical Market is booming in the US. Biological drugs are generally more expensive than the conventional drugs thus acting as key revenue earners for producers. The top categories of biologic drugs in terms of sales are …
  • 14. Figure: The US Biopharmaceuticals Market Size by Value in USD Billion, 2006-2011 70.0 60.0 50.0 40.0 USD Billion 30.0 20.0 10.0 0.0 2006 2007 2008 2009 2010 2011 IMPORTS AND EXPORTS OF PHARMACETICALS AND MEDICINES IN THE US The imports of Pharmaceuticals and medicines have increased over the period of 5 years at a CAGR of ~ to USD ~ billion in 2010. Pharmaceutical Preparations accounted for ~ of the total imports, contributing USD ~ billion in 2010 which has grown from USD ~ billion in 2005 at a CAGR of ~. Medical and botanical drugs and vitamins constituted ~ of the total Table: The US Pharmaceuticals and Medicines Exports, USD Million, 2005-2010 NAICS Code Exports (USD Million) 2005 2006 2007 2008 2009 2010 Table: The US Pharmaceuticals and Medicines Imports, USD Million, 2005-2010 NAICS Code Imports (USD Million) 2005 2006 2007 2008 2009 2010
  • 15. THE US PHARMACEUTICAL INDUSTRY FUTURE OUTLOOK AND PROJECTIONS, 2011-2015 The US Pharmaceutical industry is among the largest pharmaceutical industries in the world and is likely to be the leader in the future, ceteris paribus. But over the period, the development of new and innovative blockbuster pharmaceutical drugs has been slowing down as the number of blockbuster drugs are losing patents over the period and are being threatened by relative generic drugs. The market share of generic drugs is increasing…. …. The US pharmaceutical industry is expected to grow over the period at a CAGR ~ with projected sales of USD ~ billion in 2015. It is estimated that the research and development productivity will increase and will trigger the growth in the market. Additionally the companies will focus on … Figure: The US Pharmaceutical Industry Future Projections in Terms of Sales, in USD Billion, 2011-2015 450.0 400.0 350.0 Sales (USD Billion) 300.0 250.0 200.0 150.0 100.0 50.0 0.0 2011 2012 2013 2014 2015 Table: The US Pharmaceutical Industry Future Projections in Terms of Sales by Prescribed and OTC drugs, and Branded and Generic Drugs, USD Billion, 2011-2015 Drug Segmentation 2011 2012 2013 2014 2015 Prescribed and OTC Prescribed Drugs
  • 16. OTC Drugs % share of Prescribed drugs % share of OTC drugs Branded and Generic Branded Drugs Generic Drugs % share of Branded drugs % share of Generic drugs CAUSE AND EFFECT RELATIONSHIP BETWEEN DEPENDENT AND INDEPENDENT FACTORS PREVAILING IN THE US PHARMACEUTICALS INDUSTRY Table: Cause and Effect Relationship between Industry Factors and the US Pharmaceuticals Industry Prospects Industry Factors Market Impact Comments Increasing price of Branded drugs  Rising M&A activities and  Consolidation Advanced Technology and  competitive edge in R&D and Manufacturing Government regulations and  Support Shortage of Drugs  Expansion into Emerging Markets  Rising Chronic Diseases 
  • 17. THE US PHARMACEUTICAL INDUSTRY COMPETITIVE LANDSCAPE The US pharmaceutical industry witnessed revenues worth of USD ~ billion in 2011. Pfizer is the largest company with a market share of ~ and sales of USD ~ billion in 2011. Pfizer’s blockbuster drug, Lipitor played a major role in helping the company secure its number one position. With ~% market share in … Figure: The US Pharmaceutical Companies’ Market Share in Percentage, 2011 2011 Source: Company Reports Table: The US Pharmaceutical Companies’ Sales USD Billion, 2011 Company 2011 Sales (USD Billion) Pfizer Merck Bristol-Myers Squibb Roche AstraZeneca Novartis
  • 18. Johnson & Johnson Sanofi Amgen Eli Lilly GlaxoSmithKline Abbott Laboratories Teva Pharmaceuticals Others Total US Pharmaceutical Sales PFIZER INC. FINANCIAL PERFORMANCE Pfizer has shown a fluctuated growth over the period. The company witnessed sales of USD ~ billion in 2011 which has grown from USD ~ billion in 2005 at a CAGR of ~ The company recorded decline of ~, ~ and ~ in 2007, 2008 and 2011 respectively. The 2011 revenue decrease was due to the … Figure: Pfizer Biopharmaceutical Sales in the US, in USD Billion, 2005-2011 30.0 25.0 Sales (USD Billion) 20.0 15.0 10.0 5.0 0.0 2005 2006 2007 2008 2009 2010 2011
  • 19. DISCLAIMER No part of this manual or any material appearing may be reproduced, stored in or transmitted on any other Web site without written permission of AM Mindpower Solutions and any payments of a specified fee. Requests to republish any material may be sent to us. For more information please refer to the below mentioned link: http://ammindpower.com/report.php?A=256 OR Contact at: info@ammindpower.com